1109 related articles for article (PubMed ID: 26640245)
1. ErbB2/HER2-Specific NK Cells for Targeted Therapy of Glioblastoma.
Zhang C; Burger MC; Jennewein L; Genßler S; Schönfeld K; Zeiner P; Hattingen E; Harter PN; Mittelbronn M; Tonn T; Steinbach JP; Wels WS
J Natl Cancer Inst; 2016 May; 108(5):. PubMed ID: 26640245
[TBL] [Abstract][Full Text] [Related]
2. HER2-specific T cells target primary glioblastoma stem cells and induce regression of autologous experimental tumors.
Ahmed N; Salsman VS; Kew Y; Shaffer D; Powell S; Zhang YJ; Grossman RG; Heslop HE; Gottschalk S
Clin Cancer Res; 2010 Jan; 16(2):474-85. PubMed ID: 20068073
[TBL] [Abstract][Full Text] [Related]
3. Natural killer (NK) cells inhibit systemic metastasis of glioblastoma cells and have therapeutic effects against glioblastomas in the brain.
Lee SJ; Kang WY; Yoon Y; Jin JY; Song HJ; Her JH; Kang SM; Hwang YK; Kang KJ; Joo KM; Nam DH
BMC Cancer; 2015 Dec; 15():1011. PubMed ID: 26704632
[TBL] [Abstract][Full Text] [Related]
4. ERBB2-CAR-Engineered Cytokine-Induced Killer Cells Exhibit Both CAR-Mediated and Innate Immunity Against High-Risk Rhabdomyosarcoma.
Merker M; Wagner J; Kreyenberg H; Heim C; Moser LM; Wels WS; Bonig H; Ivics Z; Ullrich E; Klingebiel T; Bader P; Rettinger E
Front Immunol; 2020; 11():581468. PubMed ID: 33193388
[TBL] [Abstract][Full Text] [Related]
5. An Oncolytic Virus Expressing IL15/IL15Rα Combined with Off-the-Shelf EGFR-CAR NK Cells Targets Glioblastoma.
Ma R; Lu T; Li Z; Teng KY; Mansour AG; Yu M; Tian L; Xu B; Ma S; Zhang J; Barr T; Peng Y; Caligiuri MA; Yu J
Cancer Res; 2021 Jul; 81(13):3635-3648. PubMed ID: 34006525
[TBL] [Abstract][Full Text] [Related]
6. Selective inhibition of tumor growth by clonal NK cells expressing an ErbB2/HER2-specific chimeric antigen receptor.
Schönfeld K; Sahm C; Zhang C; Naundorf S; Brendel C; Odendahl M; Nowakowska P; Bönig H; Köhl U; Kloess S; Köhler S; Holtgreve-Grez H; Jauch A; Schmidt M; Schubert R; Kühlcke K; Seifried E; Klingemann HG; Rieger MA; Tonn T; Grez M; Wels WS
Mol Ther; 2015 Feb; 23(2):330-8. PubMed ID: 25373520
[TBL] [Abstract][Full Text] [Related]
7. Antitumor efficacy of chimeric antigen receptor T cells against EGFRvIII-expressing glioblastoma in C57BL/6 mice.
Chen M; Sun R; Shi B; Wang Y; Di S; Luo H; Sun Y; Li Z; Zhou M; Jiang H
Biomed Pharmacother; 2019 May; 113():108734. PubMed ID: 30849636
[TBL] [Abstract][Full Text] [Related]
8. Novel Human NK Cell Line Carrying CAR Targeting EGFRvIII Induces Antitumor Effects in Glioblastoma Cells.
Murakami T; Nakazawa T; Natsume A; Nishimura F; Nakamura M; Matsuda R; Omoto K; Tanaka Y; Shida Y; Park YS; Motoyama Y; Nakagawa I; Yamada S; Tamura K; Takeshima Y; Takamura Y; Wakabayashi T; Nakase H
Anticancer Res; 2018 Sep; 38(9):5049-5056. PubMed ID: 30194149
[TBL] [Abstract][Full Text] [Related]
9. CD19 CAR-expressing iPSC-derived NK cells effectively enhance migration and cytotoxicity into glioblastoma by targeting to the pericytes in tumor microenvironment.
Kong D; Kwon D; Moon B; Kim DH; Kim MJ; Choi J; Kang KS
Biomed Pharmacother; 2024 May; 174():116436. PubMed ID: 38508081
[TBL] [Abstract][Full Text] [Related]
10. Bispecific antibody-mediated redirection of NKG2D-CAR natural killer cells facilitates dual targeting and enhances antitumor activity.
Zhang C; Röder J; Scherer A; Bodden M; Pfeifer Serrahima J; Bhatti A; Waldmann A; Müller N; Oberoi P; Wels WS
J Immunother Cancer; 2021 Oct; 9(10):. PubMed ID: 34599028
[TBL] [Abstract][Full Text] [Related]
11. Continuously expanding CAR NK-92 cells display selective cytotoxicity against B-cell leukemia and lymphoma.
Oelsner S; Friede ME; Zhang C; Wagner J; Badura S; Bader P; Ullrich E; Ottmann OG; Klingemann H; Tonn T; Wels WS
Cytotherapy; 2017 Feb; 19(2):235-249. PubMed ID: 27887866
[TBL] [Abstract][Full Text] [Related]
12. NKG2D-Based CAR T Cells and Radiotherapy Exert Synergistic Efficacy in Glioblastoma.
Weiss T; Weller M; Guckenberger M; Sentman CL; Roth P
Cancer Res; 2018 Feb; 78(4):1031-1043. PubMed ID: 29222400
[TBL] [Abstract][Full Text] [Related]
13. Optimization of IL13Rα2-Targeted Chimeric Antigen Receptor T Cells for Improved Anti-tumor Efficacy against Glioblastoma.
Brown CE; Aguilar B; Starr R; Yang X; Chang WC; Weng L; Chang B; Sarkissian A; Brito A; Sanchez JF; Ostberg JR; D'Apuzzo M; Badie B; Barish ME; Forman SJ
Mol Ther; 2018 Jan; 26(1):31-44. PubMed ID: 29103912
[TBL] [Abstract][Full Text] [Related]
14. CAR-Engineered NK Cells for the Treatment of Glioblastoma: Turning Innate Effectors Into Precision Tools for Cancer Immunotherapy.
Burger MC; Zhang C; Harter PN; Romanski A; Strassheimer F; Senft C; Tonn T; Steinbach JP; Wels WS
Front Immunol; 2019; 10():2683. PubMed ID: 31798595
[TBL] [Abstract][Full Text] [Related]
15. KHYG-1 Cells With EGFRvIII-specific CAR Induced a Pseudoprogression-like Feature in Subcutaneous Tumours Derived from Glioblastoma-like Cells.
Nakazawa T; Murakami T; Natsume A; Nishimura F; Morimoto T; Matsuda R; Nakamura M; Yamada S; Nakagawa I; Park YS; Motoyama Y; Tsujimura T; Wakabayashi T; Nakase H
Anticancer Res; 2020 Jun; 40(6):3231-3237. PubMed ID: 32487617
[TBL] [Abstract][Full Text] [Related]
16. Specific recognition and killing of glioblastoma multiforme by interleukin 13-zetakine redirected cytolytic T cells.
Kahlon KS; Brown C; Cooper LJ; Raubitschek A; Forman SJ; Jensen MC
Cancer Res; 2004 Dec; 64(24):9160-6. PubMed ID: 15604287
[TBL] [Abstract][Full Text] [Related]
17. PD-L1 targeting high-affinity NK (t-haNK) cells induce direct antitumor effects and target suppressive MDSC populations.
Fabian KP; Padget MR; Donahue RN; Solocinski K; Robbins Y; Allen CT; Lee JH; Rabizadeh S; Soon-Shiong P; Schlom J; Hodge JW
J Immunother Cancer; 2020 May; 8(1):. PubMed ID: 32439799
[TBL] [Abstract][Full Text] [Related]
18. Targeting and Therapy of Glioblastoma in a Mouse Model Using Exosomes Derived From Natural Killer Cells.
Zhu L; Oh JM; Gangadaran P; Kalimuthu S; Baek SH; Jeong SY; Lee SW; Lee J; Ahn BC
Front Immunol; 2018; 9():824. PubMed ID: 29740437
[TBL] [Abstract][Full Text] [Related]
19. B7-H3-redirected chimeric antigen receptor T cells target glioblastoma and neurospheres.
Nehama D; Di Ianni N; Musio S; Du H; Patané M; Pollo B; Finocchiaro G; Park JJH; Dunn DE; Edwards DS; Damrauer JS; Hudson H; Floyd SR; Ferrone S; Savoldo B; Pellegatta S; Dotti G
EBioMedicine; 2019 Sep; 47():33-43. PubMed ID: 31466914
[TBL] [Abstract][Full Text] [Related]
20. Engineering NK Cells Modified With an EGFRvIII-specific Chimeric Antigen Receptor to Overexpress CXCR4 Improves Immunotherapy of CXCL12/SDF-1α-secreting Glioblastoma.
Müller N; Michen S; Tietze S; Töpfer K; Schulte A; Lamszus K; Schmitz M; Schackert G; Pastan I; Temme A
J Immunother; 2015 Jun; 38(5):197-210. PubMed ID: 25962108
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
